Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women

Pathology and Oncology Research

Volumn 13, Issue 4, 2007, Pages 360-364

  Dehaghani, Alamtaj Samsami ^a   Ghiam, Alireza Fotouhi ^b   Hosseini, Marjan ^a   Mansouri, Sareh ^a   Ghaderi, Abbas ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast health; Cancer; Menopause

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HEALTH PROGRAM; HORMONE SUBSTITUTION; HUMAN; IRAN; MENARCHE; MENOPAUSE; NORMAL HUMAN; OVARY CANCER; PARITY; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; SMOKING HABIT;

EID: 39649107714     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02940317     Document Type: Article

References (27)

1. Taechakraichana N, Jaisamrarn U, Panyakhamlerd K, Chaikittisilpa S, Limpaphayom KK: Climacteric: concept, consequence and care. J Med Assoc Thai 85:S1-15, 2002.
2. Rymer J, Morris EP: Extracts from "Clinical evidence": Menopausal symptoms. BMJ 321: 1516-1519, 2000.
3. van Asselt KM, Kok HS, Putter H, Wijmenga C, Peeters PH, van der Schouw YT, Grobbee DE, te Velde ER, Mosselman S, Pearson PL: Linkage analysis of extremely discordant and concordant sibling pairs identifies quantitative trait loci influencing variation in human menopausal age. Am J Hum Genet 74: 444-453, 2004.
4. Jamjan L, Jerayingmongkol P: Self-image of people in their fifties. Nurs Health Sci 4:A4, 2002.
5. Pike MC, Pearce CL, Wu AH: Prevention of cancers of the breast, endometrium and ovary. Oncogene 23: 6379-6391, 2004.
6. Jacobs IJ, Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3: 355-366, 2004.
7. Crump C, McIntosh MW, Urban N, Anderson G, Karlan BY: Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol Biomarkers Prev 9: 1107-1111, 2000.
8. Public Health Service. Healthy people 2010: National health promotion and disease prevention objectives - full report with commentary. Washington, DC: U.S. Department of Health and Human Services, 2000.
9. Maeda T, Inoue M, Koshiba S, Yabuki T, Aoki M, Nunokawa E, et al: Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16). J Biol Chem 279: 13174-13182, 2004.
10. Bast RC Jr: Status of tumor markers in ovarian cancer screening. J Clin Oncol 21: 200-205, 2003.
11. Zidan J, Hussein O, Basher W, Zohar S: Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma. Oncologist 9: 417-421, 2004.
12. Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M: MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 7: 209-221, 2002.
13. Clinton SR, Beason KL, Bryant S, Johnson JT, Jackson M, Wilson C, Holifield K, Vincent C, Hall M: A comparative study of four serological tumor markers for the detection of breast cancer. Biomed Sci Instrum 39: 408-414, 2003.
14. Seregni E, Botti C, Bajetta E, Ferrari L, Martinetti A, Nerini-Molteni S, Bombardieri E: Hormonal regulation of MUC1 expression. Int J Biol Markers 14: 29-35, 1999.
15. O' Rourke J, Mahon SM: A comprehensive look at the early detection of ovarian cancer. Clin J Oncol Nurs 7: 41-47, 2003.
16. Kayaba H: Tumor markers: essential diagnostic tools for radiologists. Nippon Igaku Hoshasen Gakkai Zasshi 63: 133-139, 2003.
17. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, et al: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10: 3291-3300, 2004.
18. Green BB, Taplin SH: Breast cancer screening controversies. J Am Board Fam Pract 16: 233-241, 2003.
19. Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ: Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev 10: 489-493, 2001.
20. Lopez LA, Del Villar V, Ulla M, Fernandez F, Fernandez LA, Santos I, Rabadan L, Gutierrez M: Prevalence of abnormal levels of serum tumour markers in elderly people. Age Ageing 25: 45-50, 1996.
21. Takami M, Sakamoto H, Ohtani K, Takami T, Satoh K: An evaluation of CA125 levels in 291 normal postmenopausal and 20 endometrial adenocarcinoma-bearing women before and after surgery. Cancer Lett 121: 69-72, 1997.
22. Hornstein MD, Goodman HM, Thomas PP, Knapp RC, Harlow BL: Use of a second-generation CA125 assay in gynecologic patients. Gynecol Obstet Invest 42: 196-200, 1996.
23. Cengiz B, Atabekoglu C, Cetinkaya E, Cengiz SD: Effect of hormone replacement therapy on serum levels of tumor markers in healthy postmenopausal women. Maturitas 46: 301-306, 2003.
24. Menzin AW, Kobrin S, Pollak E, Goodman DB, Rubin SC: The effect of renal function on serum levels of CA125.Gynecol Oncol 58: 375-377, 1995.
25. Brekelmans CT: Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol 15: 63-68, 2003.
26. Grover S, Quinn MA, Weideman P, Koh H: Factors influencing serum CA 125 levels in normal women. Obstet Gynecol 79: 511-514, 1992.
27. Johnson KC, Hu J, Mao Y: Passive and active smoking and breast cancer risk in Canada. Cancer Causes Control 11: 211-221, 2000.